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ABSTRACT
Immunological and clinical findings suggestive of some immune dysfunction have been 
reported among HIV-exposed uninfected (HEU) children and adolescents. Whether these 
defects are persistent or transitory is still unknown. HEU pediatric population at birth, 12 
months, 6-12 years were evaluated in comparison to healthy age-matched HIV-unexposed 
controls. Plasma levels of LPS, sCD14, cytokines, lymphocyte immunophenotyping and 
T-cell receptor excision circles (TREC) were assessed. HEU and controls had similar 
LPS levels, which remained low from birth to 6-12 years; for plasma sCD14, IL-2, IL-6, 
IL-7, IL-10, IL-12p70, IL-13, IL-17, IFN-γ, TNF-α, G-CSF, GM-CSF and MCP-1, which 
increased from birth to 12 months and then decreased at 6-12 years; and for TREC/106 
PBMC at birth in HEU and controls. By contrast, plasma MIP-1β levels were lower in 
HEU than in controls (p=0.009) at 12 months, and IL-4 levels were higher in HEU than 
controls (p=0.04) at 6-12 years. Immune activation was higher in HEU at 12 months 
and at 6-12 years than controls based on frequencies of CD38+HLA-DR+CD8+T cells 
(p=0.05) and of CD38+HLA-DR+CD4+T cells (p=0.006). Resting memory and activated 
mature B cells increased from birth to 6-12 years in both groups. The development of the 
immune system in vertically HEU individuals is comparable to the general population in 
most parameters, but subtle or transient differences exist. Their role in influencing clinical 
incidences in HEU is unknown.
KEYWORDS: HIV-exposed uninfected. Lymphocyte activation. Cytokines. 
Lipopolysaccharide. CD14 antigen.
INTRODUCTION
It is now well established that exposure to different pathogens (even in 
the absence of infection), use of antibiotics (administered both as prophylaxis 
and as treatment) and different dietary habits might direct the immune system 
towards different maturation profiles1,2. Infants born to women with human 
immunodeficiency virus (HIV) infection are associated with many such factors, with 
exposure to maternal HIV infection and associated coinfections3, maternal cytokine 
environment4, maternal vaginal microbiome5,6, antiretroviral drugs7, antibiotics used 
as prophylaxis8 and to administration of formula since birth in many countries. It is 
still not clear however how the fetus/ neonate is impacted by the degree of exposure 
to HIV during pregnancy, puerperium and early infancy and what are the immune 
consequences of this experience9,10. 
Literature on this topic has been inconclusive. A few HIV-exposed 
uninfected (HEU) children have been shown to present clinical symptoms and 
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diagnosis suggestive of some immune dysfunction such 
as Pneumocystis jiroveci pneumonia and Pseudomonas 
aeruginosa sepsis11, or a trend to more frequent low 
respiratory tract infections12. Other studies have suggested 
laboratory alterations, such as reduced CD4+ T13 and B cell 
counts11, higher immune activation14,15 and higher apoptosis 
in B cells13. It is unclear whether such alterations are 
transitory or if they persist beyond infancy. Our findings are 
informative for hitherto undescribed immune development 
in these children.
MATERIAL AND METHODS
Patients and study design
In this study, we have evaluated the presence of 
lymphocyte immune activation in HEU children and 
adolescents by assessing microbial translocation 
(lipopolysaccharide, LPS levels), monocyte activation 
(plasma sCD14 levels), plasma cytokine levels, and 
lymphocyte immunophenotyping in different age strata. We 
have also evaluated thymic function by quantifying T-cell 
receptor excision circles (TRECs) in cord blood samples. 
We used a repository of frozen plasma and cryopreserved 
peripheral blood mononuclear cell (PBMC) samples from 
preview studies in this protocol, which was approved by the 
Ethics Committee of the Federal University of São Paulo, in 
São Paulo, Brazil (protocol numbers 851/01 and 1612/04). 
Written informed consent was obtained from all parents 
prior to enrollment of children in the previous studies. 
Vertically HIV-exposed uninfected individuals were 
assessed at birth (HEU-Birth = 19), at 12 months of age 
(HEU-12 months = 19) and at 8.5 years of age (HEU-6-12 
years = 20). They were compared to age matched non-
HIV-exposed healthy children at birth (Control-Birth = 20), 
at 12 months (Control-12 months = 19) and at 8.5 years 
(Control-6-12 years = 18) (Table 1). 
All HEU individuals evaluated at birth and at 12 months, 
and 11 out of 20 (55%) 6-12 years strata received zidovudine 
for 6 weeks after birth, as prophylaxis against mother-
to-child HIV transmission. All HEU children from the 
three strata received sulfamethoxazole/ trimethoprim 
(SMZ-TMP) three times a week from then on until six 
months of age as prophylaxis against P. jiroveci mother-
to-child HIV transmission. 
Children of different ages born to healthy HIV negative 
mothers after uneventful pregnancies without evidence 
of previous serious disease were enrolled as controls. At 
assessment, they did not present any infection and were 
not on any medication. 
HEU children were regularly followed-up at the 
Pediatric AIDS Outpatient Clinic of the Federal University 
of São Paulo and they were tested for HIV infection using 
HIV DNA PCR during the first semester of life and/or 
ELISA kits for HIV antibodies after 18 months of age. 
They were considered uninfected after two negative tests.
Besides that, at the study entry, all children from the 
Control and the HEU groups were tested for HIV using 
ELISA kits to HIV antibodies. 
Plasma LPS analysis
Plasma samples were diluted to 20% with endotoxin-free 
water and were then warmed to 70 ºC for 10 min to inactivate 
plasma proteins. Plasma samples were tested in duplicate 
with a commercially available Limulus Amebocyte assay 
(Cambrex Bioscience, Walkersville, USA) according to the 
manufacturer’s protocol. Measurements were obtained on 
a kinetic absorbance reader at 450 nm (ELX800; Bio-Tek 
Instruments, Vermont, USA).
Table 1 - Demographic and clinical characteristics of control and HEU group children at different age strata
Parameters
Birth 12mo 6-12y p value for comparisons 
between Control and  
HEU groups
Control 
(n = 20)
HEU 
(n = 19)
Control 
(n = 19)
HEU 
(n = 19)
Control 
(n = 18)
HEU 
(n = 20)
Median age in years (range) 0 (0.0 – 0.0)
0 
(0.0 – 0.0)
1.0 
(0.9 – 1.0)
1.0 
(1.0 – 1.0)
8.5 
(7.0 –10.8)
8.5 
(7.8 – 10.0) p>0.05
Number of females (%) 12/20 (60)
12/19 
(63)
9/19 
(47)
12/19 
(63)
10/18 
(56)
10/20 
(50) p>0.05
Maternal smoking (%) 0/20 (0)
7/19 
(37)
3/19 
(16)
7/19 
(37) UNK UNK 0.003 (at birth)
Cesarean section (%) 1/20 (5)
19/19 
(100) UNK
19/19 
(100) UNK
3/8 
 (36)* <0.0001(at birth)
Breastfeeding (%)** NA NA 17/19 (89)
0/19 
(0) UNK
1/8 
 (12)** <0.0001(at 12 months)
UNK = unknown information. * Unknown information for 12 individuals. **Individuals who received exclusive or mixed breastfeeding. 
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Plasma sCD14 analysis
Plasma sCD14 levels were determined using human 
sCD14 ELISA kit (R&D Systems, Minneapolis, USA), 
according to the manufacturer’s specifications. Samples 
were run in duplicate on a kinetic absorbance reader 
at 450 nm (ELX800; Bio-Tek Instruments, Vermont, 
USA).
Plasma cytokine levels
Plasma cytokine (IL-1β, IL-2, IL-4, IL-5, IL-6, 
IL-7, IL-8, IL-10, IL-12 p70, IL-13, IL-17, G-CSF, 
GM-CSF, IFN-γ, MCP-1, MIP-1β and TNF-α) levels 
were determined using Bio-Plex Pro Human cytokine 
17-plex assay (Bio-Rad, Hercules, USA), according to 
the manufacturer’s specifications. Measurements were 
obtained on a Bio Plex 200 Suspension Array System 
(Bio-Rad, Austin, USA).
Flow cytometry analyses
Cryopreserved PBMC were thawed and processed if 
they had at least 85% viability. They were assessed by 
6-color flow cytometry on the same day (FACSCanto, BD 
Biosciences, Franklin Lakes, USA) after cell staining and 
they were analyzed using the FlowJo software (TreeStar, 
San Jose, USA). 
The following monoclonal antibodies were used to assess 
T, B and NK cells: CD3-FITC, CD4-PerCP, CD10-PE-Cy7, 
CD19-PerCP, CD38-FITC, CD38-PE-Cy7 (BD 
Biosciences, San Jose, USA); CD3-APC-Cy7, CD4-FITC, 
CD16-PE-Cy7, CD21-APC, CD27-PE, CD45-APC-Cy7, 
CD56-PE-Cy7, HLA-DR-PerCP, PD-1-PE (BD, San 
Jose, USA); 2B4-APC and FcRL4-APC (BioLegend, San 
Diego, USA). Isotypic controls (IgG1-FITC, IgG1-PE, 
IgG2a-PerCP, IgG1-PE-Cy7, IgG1-APC, IgG2b-APC, from 
BD Biosciences, San Jose, USA; IgG1-PE and IgG1-APC, 
from BioLegend, San Diego, USA) were used to evaluate 
nonspecific staining.
CD4+T cells were defined as CD3+CD4+ and CD8+T 
cells were defined as CD3+CD4-, and evaluated for 
frequencies of activated (CD38+HLA-DR+); or exhausted 
(PD-1+ or 2B4+) cell subset. B cells were defined as 
CD3-CD19+, and evaluated for frequencies of transitional 
(CD10+), naïve (CD10-CD21+CD27-), resting memory 
(CD10-CD21+CD27+), activated mature (CD10-CD21-
CD27+) and exhausted memory B cells (CD10-CD21-
CD27- or PD-1+ or FcRL4+). 
NK cells were defined as CD45+CD3-CD16+CD56+ 
and evaluated for frequencies of PD-1+ exhausted cells.
Quantification of TRECs
DNA was extracted from frozen PBMCs using 
the QIAamp DNA Mini and Blood Mini kit (QIAgen, 
Valencia, USA). TRECs were quantified by real-
time PCR, in an ABI 7500 Real Time PCR system 
(Applied Biosystems, Foster City, USA). In brief, 
0.5 mM primers (CACATCCCTTTCAACCATGCT 
and GCCAGCTGCAGGGTTTAGG) (Sigma-Aldrich, 
Saint Louis, USA), 0.2 mM TaqMan probe FAM-
ACACCTCTGGTTTTTGTAAAGGTGCCCACT-BHQ1 
(Sigma-Aldrich, Saint Louis, USA), 0.025 U of Platinum 
Taq polymerase, 3.5 mM MgCl2, 0.2 mM dNTPs in TaqMan 
buffer (Invitrogen, Carlsbad, USA) and 5 uL of genomic 
DNA were mixed in a total volume of 25 uL. A total of 5 
uL of DNA was used for the TREC assay. PCR conditions 
were 95 °C for 5 min. and 40 cycles of 95 °C for 30 sec., 
and 60 °C for 1 min. A standard curve was included in every 
PCR reaction for the absolute quantification of the number 
of TRECs per 106 cells of PBMC in each sample. TREC 
fragments were generously provided by Dr. Daniel Douek. 
The TREC standard curve was established using seven 10-
fold dilutions ranging from 102 to 108 TREC copies/5 uL 
of plasmids containing the TREC fragment. Each sample 
was run in duplicate and average TREC values were used 
for data analysis. Results were expressed as TRECs per 
106 cells. During the process of assay standardization, 
TRECs from cord blood lymphocytes were compared to 
PBMC samples from healthy adults aged 23 to 35 years. 
Statistical analysis
Continuous variables were analyzed by the Mann-
Whitney test; if more than two groups were tested, Kruskal-
Wallis test (KW) and Student-Newman-Keuls were used. 
Categorical variables were analyzed by the chi-squared test.
Pearson’s correlation coefficient was assessed for 
CD4+ T cell counts and frequencies of activated or 
exhausted subsets. 
For all analyses, Minitab 14 (Minitab, State College, 
USA) and BioEstat 5.0 (Instituto de Desenvolvimento 
Sustentável Mamirauá, Tefé, Brazil) were employed. The 
level of significance was set at p<0.05.
RESULTS
Demographic data
Demographic and clinical data are presented on Table 1.
In the vast majority of mothers (77%) of two groups 
of HEU children (birth and 12-month groups), HIV viral 
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loads close to delivery were lower than 400 copies/mL. In 
the other 23% of mothers, viral load varied from 1,310 to 
26,400 copies/ mL. No information on maternal viral load 
was available for the 6-12 years old strata.
Seventeen infants (89%) from control-12 months group 
had exclusive or mixed breastfeeding for a median of 6.8 
months; by contrast, no child from HEU-12 months group 
was breastfed (χ2, p < 0.0001). Breastfeeding information 
was not available from the 6-12 years control-group. 
Only one individual from the HEU-6-12 earsy group was 
breastfed for 3 days, which occurred before his mother was 
diagnosed with HIV infection (Table 1). 
Plasma LPS and sCD14 levels
Plasma LPS levels were similar among HEU and 
control children and did not vary with age from birth until 
6-12 years of age (KW, p=0.189) (Figure 1). By contrast, 
plasma sCD14 levels increased significantly from birth to 12 
months of age independently of HIV exposure (Figure 1). A 
slight decay in plasma sCD14 levels was observed from 12 
months to 6-12 years, but that was only significant for HEU 
children (Figure 1). No differences were noted between 
HEU and C-control groups within any age strata (Figure 1). 
Plasma cytokine levels
Plasma levels from 17 cytokines were assessed ex vivo, 
without any in vitro stimulus. The majority of cytokines 
(IL-1β, IL-2, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 p70, 
IL-13, IL-17, IFN-γ, TNF-α, G-CSF, GM-CSF and MCP-1) 
showed some variation with age and many of them peaked 
at 12 months of age (IL-2, IL-6, IL-7, IL-10, IL-12 p70, 
IL-13, IL-17, IFN-γ, TNF-α, G-CSF, GM-CSF and MCP-1) 
(Table 2). The HEU group differed from the control group 
with respect to two cytokines on different occasions: 
median IL-4 levels were higher at 6-12 years in HEU 
than in C-controls (1.0 versus 0.6 pg/ mL; KW, p=0.043); 
median MIP-1β levels, by contrast, were lower in HEU at 
12 months when compared with C-controls (23.9 versus 
46.0 pg/ mL; KW, p=0.009). 
IL-5 was the only cytokine from which no statistical 
differences were noted among groups at any age (KW, 
p=0.588).
Activation and exhaustion markers by flow cytometry
An increase in the expression of activation markers 
was observed on CD8+ T cells from birth to 12 months of 
age for HEU followed by a decrease at 6-12 years in HEU 
(p=0.011 and p=0.001, respectively) (Table 3). CD4+ T cell 
effects were less striking but followed a similar pattern. The 
HEU group had a higher frequency of CD38+HLA-DR+ 
CD8+T cells than controls at 12 months of age (p=0.053) 
and a higher frequency of CD38+HLA-DR+CD4+T cells 
than controls at 6-12 years (p=0.006).
PD-1 expression on CD4+ T cells increased at 12 
months and was maintained on that level until 6-12 years 
(Table 3). On the other hand, PD-1 expression on CD8+ T 
cells increased at 12 months and decreased at 6-12 years 
(Table 3). 2B4 expression on CD4+ T cells increased at 
12 months in controls and at 6-12 years in HEU (Table 3); 
2B4 expression on CD8+ T cells increased at 12 months 
and was maintained on that level until 6-12 years (Table 3).
Figure 1 - Plasma LPS levels and sCD14 levels in control and HEU groups at different ages (Birth, 12mo and 6-12y). Outliers are 
represented by circles. Differences between HEU children at different age strata are shown as solid lines; differences between 
control children at different age strata are shown as dashed lines
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Table 2 - Median plasma cytokines in control and HEU groups at different ages, with interquartile values in parenthesis
Birth 12 mo 6-12 y p values
Control 
(n=20)
HEU 
(n=19)
Control 
(n=19)
HEU 
(n=19)
Control 
(n=18)
HEU 
(n=20)
HEU vs. 
Control
Control at different 
ages
HEU at different 
ages
IL-1β 1.8 (1.0, 6.5)
1.9 
(0.9, 6.3)
1.0 
(0.8, 1.4)
1.2 
(0.7, 1.1)
0.8 
(0.5, 1.1)
0.9 
(0.7, 1.2) p>0.05
0.014(birth-12mo) 
0.001(birth-6-12y) 0.001(birth-6-12y)
IL-2 2.0 (1.7, 2.1)
2.0 
(1.5, 2.0)
2.4 
(2.0, 4.5)
2.9 
(2.0, 6.4)
2.0 
(1.5, 3.0)
2.0 
(2.0, 3.0) p>0.05 0.038(birth-12mo) 0.006(birth-12mo)
IL-4 0.9 (0.6, 1.3)
0.7 
(0.6, 1.1)
1.0 
(0.7, 1.2)
1.1 
(0.8, 1.6)
0.6 
(0.5, 0.9)
1.0 
(0.7, 1.1)
0.043 (6-
12y)
0.024(birth-6-12y) 
0.004(12mo-6-12y) 0.017(birth-12mo)
IL-5 4.3 (2.2, 4.4)
2.7 
(1.7, 4.4)
4.4 
(3.0, 4.4)
4.3 
(2.9, 4.4)
4.2 
(1.8, 4.4)
4.4 
(2.3, 4.4) p>0.05 p>0.05 p>0.05
IL-6 2.4 (2.4, 2.7)
2.4 
(2.5, 3.2)
5.3 
(2.5, 9.8)
4.6 
(2.7, 8.6)
3.7 
(2.5, 7.0)
2.9 
(2.5, 5.9) p>0.05
0.012(birth-12mo) 
0.009(birth-6-12y) 0.008(birth-12mo)
IL-7 2.4 (1.9, 3.1)
2.4 
(1.8, 2.9)
3.1 
(2.6, 3.6)
3.2 
(2.1, 3.7)
2.0 
(1.7, 3.2)
2.1 
(1.6, 2.9) p>0.05 0.031(birth-12mo) 0.023(12mo-6-12y)
IL-8 3.8 (3.8, 20.2)
5.5 
(3.8, 7.4)
3.8 
(3.6, 5.7)
3.8 
(3.4, 3.8)
3.8 
(3.8, 3.8)
3.8 
(3.0, 3.8) p>0.05 0.029(birth-6-12y)
0.007(birth-12mo) 
0.004(birth-6-12y)
IL-10 1.4 (1.0, 1.9)
1.4 
(0.9, 2.0)
4.7 
(2.7, 10.6)
4.1 
(1.5, 7.4)
3.8 
(1.4, 6.6)
2.6 
(1.4, 14.1) p>0.05
0.001(birth-12mo) 
0.007(birth-6-12y)
0.001(birth-12mo) 
0.002(birth-6-12y)
IL-12 (p70) 1.1 (0.9, 2.1)
1.1 
(0.8, 1.4)
3.0 
(2.1, 5.0)
1.9 
(1.3, 3.7)
2.2 
(1.3, 3.3)
1.8 
(1.3, 3.7) p>0.05
0.001(birth-12mo) 
0.028(birth-6-12y)
0.001(birth-12mo) 
0.003(birth-6-12y)
IL-13 2.6 (2.2, 2.8)
2.4 
(2.0, 2.6)
4.0 
(2.9, 6.1)
4.0 
(2.7, 5.0)
3.7 
(2.5, 5.5)
4.8 
(3.1, 6.6) p>0.05
0.001(birth-12mo) 
0.019(birth-6-12y)
0.001(birth-12mo) 
0.001(birth-6-12y)
IL-17 3.3 (3.0, 5.2)
3.0 
(2.4, 4.2)
4.1 
(3.1, 6.0)
4.5 
(2.9, 6.9)
3.0 
(1.6, 4.0)
3.0 
(2.2, 3.2) p>0.05 0.018(birth-12mo) 0.006(12mo-6-12y)
IFN-γ 35.5 (25.5, 59.7)
36.2 
(18.7, 57.7)
43.7 
(37.1, 62.0)
53.2 
(30.3, 74.0)
31.6 
(19.4, 44.7)
31.7 
(24.3, 42.7) p>0.05 0.029 (12mo-6-12y)
0.029(birth-12mo) 
0.019 (12mo-6-12y)
TNF-α 12.0 (7.2, 15.0)
8.5 
(4.8, 11.1)
12.8 
(10.9, 20.7)
22.4 
(8.7, 25.1)
7.7 
(5.8, 13.6)
10.5 
(6.6, 13.4) p>0.05 0.015 (12mo-6-12y)
0.001(birth-12mo) 
0.031 (12mo-6-12y)
G-CSF 8.9 (5.6, 11.4)
7.9 
(5.4, 13.2)
11.4 
(7.9, 16.6)
11.3 
(6.6, 14.7)
5.8 
(4.2, 8.2)
6.0 
(4.4, 8.2) p>0.05
0.049(birth-6-12y) 
0.001 (12mo-6-12y) 0.001 (12mo-6-12y)
GM-CSF 41.3 (25.1, 53.9)
33.1 
(27.9, 51.1)
43.6 
(32.3, 52.4)
51.3 
(25.5, 77.9)
20.6 
(16.5, 34.1)
26.6 
(19.7, 34.3) p>0.05
0.004(birth-6-12y) 
0.002 (12mo-6-12y)
0.050(birth-6-12y) 
0.001 (12mo-6-12y)
MCP-1 13.2 (9.2, 15.5)
14.4 
(8.5, 26.1)
24.0 
(19.6, 36.0)
22.4 
(18.5, 32.7)
17.7 
(11.6, 45.3)
20.1 
(15.7, 27.6) p>0.05
0.001(birth-12mo) 
0.017(birth-6-12y) 0.006(birth-12mo)
MIP-1β 31.7 (22.5, 81.2)
41.2 
(24.6, 93.2)
46.0 
(29.1, 71.0)
23.9 
(21.5, 35.4)
28.0 
(19.8, 61.7)
25.2 
(19.6, 38.8)
0.009 
(12mo) p>0.05
0.023(birth-12mo) 
0.028(birth-6-12y)
Table 3 - Median T lymphocytes subset percentages in -control and HEU groups at different ages, with interquartile values in 
parenthesis
Parameters
Birth 12 mo 6-12 y p values
Control HEU Control HEU Control HEU HEU vs. Control
Control at different 
ages
HEU at different 
ages
CD4+ T cells
%CD38+ HLA-DR+ 1.4 (1.2, 2.0)
1.8 
(1.7, 2.2)
4.0 
(2.8, 5.9)
2.3 
(1.5, 4.6)
1.7 
(1.6, 2.2)
2.9 
(2.0, 4.9)
0.006 
(6-12y)
0.005(birth-12mo) 
0.005(12mo-6-12y) 0.038(birth-6-12y)
% PD-1+ 3.2 (2.2, 4.5)
1.8 
(1.3, 3.4)
10.4 
(9.2, 14.8)
10.9 
(5.5, 23.5)
10.4 
(7.4, 13.6)
12.0 
(8.3, 18.5) p>0.05
0.008(birth-12mo) 
0.004(birth-6-12y)
0.002(birth-12mo) 
0.001(birth-6-12y)
% 2B4+ 1.9 (0.2, 2.6)
1.7 
(0.7, 3.1)
5.9 
(4.2, 7.5)
2.1 
(0.7, 5.3)
5.4 
(2.3, 10.0)
10.3 
(4.4, 16.1) p>0.05
0.030(birth-12mo) 
0.004(birth-6-12y)
0.001(birth-6-12y) 
0.002(12mo-6-12y)
CD8+ T cells
%CD38+ HLA-DR+ 12.1 (9.3, 15.9)
9.6 
(6.8, 15.5)
12.2 
(8.2, 15.3)
18.6 
(16.0, 25.6)
5.6 
(4.4, 6.9)
7.8 
(5.9, 14.3)
0.053 
(12mo) 0.001(birth-6-12y)
0.011(birth-12mo) 
0.001(12mo-6-12y)
% PD-1+ 7.8 (6.2, 11.3)
4.9 
(4.2, 8.0)
18.6 
(11.5, 26.2)
15.3 
(10.8, 24.3)
11.6 
(7.4, 15.1)
6.3 
(3.7, 22.5) p>0.05 0.026(birth-12mo) 0.009(birth-12mo)
% 2B4+ 14.7 (11.9, 23.1)
14.7 
(12.4, 20.1)
57.4 
(41.3, 60.4)
40.5 
(30.9, 53.2)
44.8 
(38.3, 56.1)
48.9 
(44.0, 66.0) p>0.05
0.001(birth-12mo) 
0.001(birth-6-12y)
0.008(birth-12mo) 
0.001(birth-6-12y)
Miyamoto et al.
Rev Inst Med Trop São Paulo. 2017;59:e30Page 6 of 9
The percentage of transitional B cells decreased after 
12 months of age in both groups (Table 4). Naïve B cells 
did not show any statistical difference when groups or ages 
strata were assessed (Table 4). Resting memory B cell 
percentages increased from birth and reached the highest 
levels at 6-12 years for control and HEU groups (Table 4). 
The percentage of activated mature B cells increased after 
12 months in both groups (Table 4). Exhausted memory B 
cells decreased from birth to 12 months and had a small 
increase at 6-12 years of age in both groups (Table 4). 
CD38 expression on B cells decreased after birth in both 
groups (Table 4). 
There were no statistical differences between groups for 
PD-1 and FcRL4 expression on B cells (p=0.178, p=0.066, 
respectively), neither was there for PD-1 expression on NK 
cells (p=0.295) (Table 4).
Correlation between CD4+ T cell counts and 
exhaustion and activation markers
A strong inverse correlation between CD4+T cell counts 
and CD38+HLA-DR+ on CD8+T cells was observed in 
HEU individuals aged 12 months (r = -0.677, p = 0.032).
Similarly, a strong inverse correlation between CD4+T 
cell counts and PD-1 expression on CD4+T and CD8+T 
cells was observed in HEU individuals aged 12 months 
(CD4+PD-1+: r = -0.655, p = 0.040; CD8+PD-1+: 
r = -0.730, p = 0.016).
TRECs in PBMC
The median number of TREC copies/ 106 PBMC on 
cord samples was similar between HEU and control groups 
(HEU: 52646, Controls: 64322, p=0.800). 
DISCUSSION
The results from this study suggest that HIV-exposed 
uninfected children have a similar pattern and share many 
immunological aspects after birth with healthy age-matched 
controls. Both had low levels of microbial translocation 
markers in plasma in all age strata with ascending 
levels from birth to 12 months and a subsequent drop at 
6-12 years for sCD14 and concurrently for 12 of the 17 
cytokines analyzed. Also, no evidence of damage to thymus 
function at birth was noted in HEU. There were only a few 
differences. Among plasma cytokines, HEU had lower 
plasma MIP-1β levels at 12 months and higher IL-4 levels at 
6-12 years when compared to controls at similar age strata. 
HEU also showed higher activation markers on CD8+ T 
cells at 12 months and on CD4+ T cells at 6-12 years than 
the -control group. These differences could be attributed to 
Table 4 - Median B and NK cell subsets in control and HEU groups at different ages, with interquartile values in parenthesis
Parameters
Birth 12 mo 6-12 y p values
Control HEU Control HEU Control HEU HEU vs. Control
Control at different 
ages
HEU at different 
ages
B cells
%Transitional (CD10+) 63.1 (58.3, 66.7)
62.7 
(57.6, 64.4)
59.1 
(56.2, 77.0)
59.2 
(53.0, 62.0)
49.9 
(47.1, 50.8)
53.9 
(52.8, 57.0) p>0.050
0.001(birth-6-12y) 
0.001(12mo-6-12y) 0.043(birth-6-12y)
%Naïve  
(CD10-CD21+CD27-)
73.7 
(58.8, 84.8)
53.5 
(38.2, 73.6)
77.5 
(69.0, 85.5)
81.9 
(77.1, 87.5)
75.0 
(63.3, 78.8)
63.3 
(53.6, 71.6) p>0.050 p>0.050 p>0.050
%Resting memory 
(CD10-CD21+CD27+)
0.9 
(0.5, 1.4)
0.8 
(0.4, 1.6)
3.8 
(2.0, 7.1)
2.2 
(1.7, 4.1)
8.5 
(6.1, 11.6)
6.4 
(4.7, 11.6) p>0.050
0.010(birth-12mo) 
0.001(birth-6-12y)
0.038(birth-12mo) 
0.001(birth-6-12y)
% Activated Mature 
(CD10-CD21-CD27+)
1.4 
(0.8, 2.0)
2.6 
(0.6, 3.5)
2.8 
(1.9, 5.1)
2.7 
(1.8, 3.2)
4.4 
(3.2, 8.8)
6.1 
(4.5, 9.7) p>0.050
0.037(birth-12mo) 
0.001(birth-6-12y) 0.001(birth-6-12y)
% Exhausted Memory 
(CD10-CD21-CD27-)
23.1 
(13.1, 39.3)
40.2 
(22.1, 58.1)
10.3 
(7.9, 17.8)
11.1 
(4.8,13.9)
12.8 
(7.9, 15.9)
22.2 
(13.2, 23.6) p>0.050
0.047(birth-12mo) 
0.040(birth-6-12y)
0.001(birth-12mo) 
0.047(birth-6-12y)
% CD38+ 42.8 (29.0, 48.5)
37.8 
(29.7, 21.3)
33.3 
(26.0, 40.0)
35.9 
(32.5, 39.5)
13.1 
(9.3, 15.4)
13.4 
(6.6, 31.7) p>0.050
0.001(birth-6-12y) 
0.005(12mo-6-12y)
0.024(birth-6-12y) 
0.010(12mo-6-12y)
% PD-1+ 0.2 (0.0, 0.8)
0.7 
(0.2, 1.6)
0.1 
(0.1, 0.1)
0.1 
(0.1, 0.2)
0.4 
(0.3, 0.5)
0.5 
(0.3, 1.9) p>0.050 p>0.050 p>0.050
% FcRL4+ 0.5 (0.3, 0.8)
1.7 
(1.0, 2.3)
1.9 
(1.6, 2.4)
0.8 
(0.7, 0.9)
3.1 
(1.1, 6.3)
1.1 
(0.6, 1.9) p>0.050 p>0.050 p>0.050
NK cells
% PD-1+ 0.7 (0.3, 1.6)
1.6 
(0.6, 2.8)
0.6 
(0.5, 0.8)
0.6 
(0.5, 0.7)
0.4 
(0.2, 0.8)
1.5 
(1.4, 2.1) p>0.050 p>0.050 p>0.050
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HIV exposure or may be unrelated. The similarities were 
greater than the differences, indicating that HEU are not 
significantly immune compromised. Moreover, this study 
provided valuable insight into the development of the 
immune system over the first year of life.
The cytokines IL-2, IL-6, IL-7, IL-10, IL-12p70, 
IL-13, IL-17, IFN-γ, TNF-α, G-CSF, GM-CSF and 
MCP-1 followed a similar pattern in the two groups. They 
showed an increase in the first 12 months of age, lower 
at 6-12 years. That pattern might reflect exposure to both 
environmental and vaccine antigens during the first year of 
life, as previously observed16. In contrast, two cytokines, 
plasma MIP-1β and IL-4 levels followed a different pattern 
in HEU than in controls. 
Plasma MIP-1β levels were higher in HEU at birth 
as compared to levels at 12 months and at 6-12 years, 
whereas in controls MIP-1β levels increased from birth 
to 12 months, such that levels at 12 months were higher 
in controls than in HEU. MIP-1α, MIP-1β and RANTES 
are β-chemokines and as natural ligands of CCR5, they 
are known to interfere with HIV infection. HIV-exposed 
uninfected adults at increased risk of infection demonstrate 
higher β-chemokine levels than non-HIV-exposed adults, 
suggesting that β-chemokines are amongst the factors that 
prevent HIV infection in some individuals17. Recently, 
some elite controllers were shown to express higher levels 
of plasma MIP-1β levels and this was sufficient to block 
R5-tropic HIV entry18. In this way, the higher MIP-1β levels 
at birth when compared to 12 months in the HEU group may 
indicate an appropriate immune response to a limited period 
of HIV exposure19. The higher IL-4 levels at 6-12 years in 
HEU that contrasted with controls, could be an indicator of 
a predominant Th2 response in the HEU group, although 
we could not corroborate this with additional studies or 
clinical findings. 
Immune activation is a feature of many inflammatory 
conditions including chronic HIV infection and has been 
attributed to different factors such as microbial translocation 
and HIV medicated immune activation. Somewhat 
surprising was the higher activation markers on CD8+ T 
cells at 12 months and on CD4+ T cells at 6-12 years in HEU 
compared to the control group. Other studies have shown 
higher CD38+ expression on CD8+T cells in HEU than HIV-
unexposed individuals at different ages14,15. This difference 
might represent transitory immune activation due to HIV 
exposure in the peripartum and, possibly, a consequent late 
maturation of the immune system. The inverse correlation 
observed between CD4+ T cell counts and exhausted/ 
activated CD8+ T cells reinforce the possibility that, at least 
for some individuals, an inflammatory environment might 
contribute to lower CD4+ T cell levels.
No statistical differences were noted between HEU and 
control groups in respect to B and NK cells at any of the 
three age-strata analyzed. As most HEU children analyzed 
in this study had mothers with low viral load copies at 
delivery, the intensity of HIV exposure was presumably 
insufficient to have influenced B and NK cells significantly.
The first postnatal year of life seems to be a key 
period for programming the immune system. Recently, 
attention has been focused on the establishment of the 
gut microbiota, since it contributes to the maturation of 
the immune system1,2,20. Feeding and other factors such 
as use of antibiotics may influence the gut microbial and 
the intestinal epithelial integrity2,21-23. In our study, most 
HEU individuals were formula-fed,as one of the preventive 
strategies against vertical HIV infection, and SMZ-TMP 
was given to all HEU infants. Both the formula-feeding 
and antibiotic therapy cohort may have interfered in the 
gut/ airway microbiota establishment, thus contributing to 
an altered immune system profile in some aspects. 
Similar to what was previously shown24, we did not 
find differences between HEU and healthy HIV-unexposed 
population in regard to the number of TREC in CD4+T 
cells, suggesting that there is no damage in thymus function.
This study had some limitations. We evaluated a small 
number of individuals who were not from a longitudinal 
cohort. Also, similar to exposure to antiretrovirals and 
antibiotics and to the choice of caesarean section, some 
characteristics such as breastfeeding and maternal smoking 
differed between groups. However, those are characteristics 
of the environment of HEU infants and it is very difficult 
to isolate the influence of each of these variables on the 
child’s immune system.
Despite the small number of individuals in each group, 
we demonstrated that HEU infants and children whose 
mothers were on ARV during pregnancy had few alterations 
in comparison to healthy controls. We have also looked 
at long-term consequences by studying older children, 
and found very little immunological abnormalities or 
clinical consequences in this cohort. These changes may 
be due to HIV exposure, mainly in the peripartum, and/or 
altered microbiota development with consequences such 
as impairment in the maturation of the immune system, 
possible imbalance of cytokine production and poor 
immune response against antigens.
Depending on the intensity of exposure to different 
stimuli, a different clinical profile might be present. A HIV-
infected pregnant woman with an undetectable HIV viral 
load might expose her fetus to a less modified environment 
that one with a high viral load and a very activated immune 
system. In this way, medical advances that contribute to an 
adequate control of HIV infection and their consequences to 
Miyamoto et al.
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the maternal immune system do also contribute to provide 
the fetus with a less modified environment. Of note, none of 
the HEU children evaluated presented any serious disease. 
In summary, our study shows that the immune system 
of HIV-exposed uninfected children is, for the majority 
of analyzed parameters, comparable to non-HIV-exposed 
children. Although many cytokines and activation markers 
appear to be more intensively expressed in the first year 
of life, probably due to antigenic exposure, the immune 
system seems to go back to homeostasis after that period. 
It is unclear whether the few alterations observed among 
HIV-exposed uninfected children will turn into immune 
disorders in the future. More long-term studies that monitor 
those changes observed in this heterogeneous population 
might be able to answer that question.
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